The pitch in one line: MEC sells a few hundred yen of chemistry per substrate panel, but it is the chemistry that lets PCB fabs hit the adhesion, dielectric-loss and laser-drill specs that AI servers, ABF substrates and 5G AiP modules now demand.
MEC Company Ltd. (4971.T) is a Japanese specialty chemicals company selling microetching and surface-treatment chemistries to the printed circuit board and IC substrate supply chain. The franchise rests on one product family — the CZ-series copper microetchant — which has effectively monopolised inner-layer copper roughening for high-end multilayer PCBs and ABF substrate cores for two decades. Per sponsored research, MEC claims ~100% global share in copper surface treatment for PC CPU substrates, and CZ accounts for roughly half of corporate revenue.
The pitch in one line: MEC sells a few hundred yen of chemistry per substrate panel, but it is the chemistry that lets PCB fabs hit the adhesion, dielectric-loss and laser-drill specs that AI servers, ABF substrates and 5G AiP modules now demand. Layer-count expansion, finer line/space and tighter loss budgets all increase consumption intensity per board — a volume-and-mix story, not just a unit-growth story.
| Field | Value |
|---|---|
| Legal name | MEC Company Ltd. (メック株式会社) |
| Ticker | 4971.T (TSE Prime) |
| GICS | Materials / Specialty Chemicals |
| HQ | Amagasaki, Hyogo, Japan |
| Founded | 1969 |
| Employees | 508 (Dec-2025) |
| Currency | JPY (fiscal year = Dec) |
| Website | https://www.mec-co.com |
| Latest IR deck | 2030 Vision Phase 2 (Feb 13, 2026) |
Business lines (no formal segment disclosure beyond geography; product mix per IR commentary):
Business model. Recurring consumable chemistry sold by the litre/kg through long-qualified specifications at PCB and substrate fabs. Customers cannot swap suppliers without re-qualifying the board recipe with their end-customer (Intel, AMD, Nvidia, Apple). High switching cost, low individual ASP. Gross margin 61.6% (FY2025); operating margin 27.4% (FY2025) — software-grade margins for a chemicals business, which is the signal that this is closer to a specialty platform than a commodity etchant.
Geographic revenue mix (six reporting bases): Japan, Taiwan, Suzhou (China), Zhuhai (China), Thailand, Europe. Asia ex-Japan is the majority — Taiwan and Suzhou handle the highest-end PCB and ABF substrate work.
Asset map / facility deck is inside the Feb-2026 medium-term plan PDF (linked above); no clean public-URL image to embed.
None disclosed at the corporate level. MEC operates wholly-owned subsidiaries in each geography rather than JVs. Commercial relationships with PCB fabs are pure supplier–customer, not equity-linked.
MEC does not publicly disclose named customers. The list below is inferred from end-use commentary (AI server PCB, IC substrate, 5G AiP) and the PCB/substrate cluster geography. Inference, not disclosure.
| # | Likely Customer | Ticker | Est. Revenue Share | Relationship Type |
|---|---|---|---|---|
| 1 | Ibiden | 4062.T | not disclosed | ABF IC substrate — CZ for substrate cores |
| 2 | Unimicron | 3037.TW | not disclosed | ABF IC substrate + HDI PCB |
| 3 | Compeq / Tripod / Nan Ya PCB | 2313.TW / 3044.TW / 8046.TW | not disclosed | AI server HDI PCB |
| 4 | Shinko Electric | 6967.T | not disclosed | IC substrate |
| 5 | Kinsus / Simmtech | 3189.TW / KQ:222800 | not disclosed | IC substrate, memory substrate |
Concentration risk. Undisclosed. The CZ ~100% PC CPU substrate share claim implies that any single ABF substrate house is a meaningful customer, with Ibiden and Unimicron likely the top two. MEC has not published a top-customer %.
Dependency flag. If Korean (Samsung, LG Innotek) or Chinese (Shennan, Victory Giant) substrate entrants displace incumbents and specify different surface-treatment chemistry, MEC loses with the incumbents even though CZ itself is not the loser. Suzhou plant expansion is the de-risking move.
Why it matters. Every advanced multilayer PCB and IC substrate built today needs a roughened copper surface so the next dielectric layer adheres without delaminating. As line/space shrinks (HDI → mSAP → ABF) and dielectric loss budgets tighten (M9-grade CCL, Megtron 8/M9), conventional brown-oxide roughening leaves copper too rough — signal loss and yield collapse. CZ gives a controlled ~0.1µm roughness profile that holds adhesion without killing high-frequency loss. This is why CZ has held share through 20 years of PCB tech transitions while competitors (Atotech/MKS, Uyemura) rotated through alternatives.
End-use applications:
TAM. Specialty PCB/substrate chemistry is not cleanly broken out by IDC/Prismark. Closest proxy is the wet-process chemical line item inside the ~$80B PCB market and ~$15B substrate market. Order of magnitude: $2-3B annual addressable spend across copper adhesion, microetching and cleaning. MEC’s revenue of ~$140M USD on ¥21B implies high-single-digit share of total etch/adhesion chemistry, dominated by the high-value CZ niche.
Secular tailwinds:
ai-server-pcb-primer.md).Japanese small-cap; English disclosure on executives and board is limited. Standard Japanese governance applies (Representative Director, statutory auditors, independent outside directors required under Corporate Governance Code).
| Name | Title | Tenure | Background |
|---|---|---|---|
| Kazuo Maeda | Representative Director, President & CEO | President since 2002 (~24yr); CEO since 2015 (~11yr) | Career MEC operator; led Asia international build-out (Zhuhai, Taiwan, HK, Suzhou) before CEO seat |
| Sadamitsu Sumitomo | Director, EOO Global Operations | ~5.2yr on board | Internal — Maeda-team operator |
| Tetsuya Taniguchi | Director, EOO | ~1.3yr on board (joined early 2025) | Recent internal promotion; likely succession candidate |
| Katsuaki Kitauji | Operating Officer, GM Accounting & Finance | from May 2025 | Below-board financial lead; Japan small-cap pattern |
Board composition. TSE Prime listed → required to have at least one-third independent outside directors; MEC has met this standard since the listing-tier reclassification.
Alignment & activity:
Top competitors:
Moat:
Porter snapshot. Low rivalry at the high end (CZ ~100% PC CPU share), moderate at legacy. Commodity input suppliers (sulfuric acid, hydrogen peroxide). Asymmetric buyer power — re-qual cost > chemistry cost. High barriers to new entrants (qualification + IP + 20 years of process data). Direct-bonding adhesion (AMALPHA-style) is the next-gen substitute and MEC owns the in-house option.
All JPY unless noted. FY = calendar year (Dec). Live data 2026-05-15, EOD.
Valuation (current, 2026-05-15)
| Metric | Value | Δ vs 2026-05-12 |
|---|---|---|
| Share price | ¥11,050 | -1.3% (¥11,190 → ¥11,050) |
| 5-day range | ¥10,350 – ¥12,230 | new 52w high ¥12,230 on 5/14 |
| Market cap | ¥201.8B (~$1.34B USD at 150) | -¥2.5B |
| Enterprise value | ¥217.8B | up — reflects refreshed EV calc with Q1 cash position |
| P/E (TTM) | 40.5x | tightening (was 41.1x) |
| Forward P/E (FY+1) | 56.9x | flat (was 57.7x) |
| EV/EBITDA (TTM) | ~75.7x | depressed by Q1-windowed EBITDA; use FY2025 EBITDA ¥7.3B → ~29.8x EV/EBITDA |
| P/B | 14.5x | tightening from 14.7x |
| Dividend yield | 0.95% | small uptick |
| 52-week range | ¥2,385 – ¥12,230 | high refreshed up |
| Beta | 1.06 | unchanged |
The stock is now +363% off the 52-week low (¥2,385).
Two-day fade from the ¥12,230 high to ¥11,050 = -9.6% on slightly
elevated volume — looks like profit-taking after Q1 print and the
medium-term plan re-rating digestion, not a thesis crack. Valuation
tension remains the central question — DCF and /dcf skill
should be run before sizing.
Income statement & margins
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|---|
| Revenue | ¥16.3B | ¥13.5B | ¥18.2B | ¥20.9B | ¥23.8B |
| Revenue growth YoY | — | -17% | +35% | +14.9% | +13.8% |
| Gross margin | 60.0% | n/a | n/a | 61.6% | n/a |
| Operating margin | 24.5% | n/a | n/a | 27.4% | n/a |
| Net margin | 18.8% | n/a | n/a | 24.0% | n/a |
| EPS (diluted) | ¥161 | n/a | n/a | ¥272 | ¥275 (n=2 consensus) |
Q1 FY2026 (filed 2026-05-12): Diluted EPS ¥25.44; basic ¥25.44 on 18.73M weighted shares. Annualised run-rate ¥101.76 — well below the ¥275 FY2026E consensus, but Q1 is seasonally the weakest quarter for MEC and the AI server PCB ramp loads back-half. Revenue growth YoY at the TTM-step level shows +87.7% in yfinance’s revenueGrowth field — that is the TTM-vs-prior-TTM step from the AI server PCB inflection. Q2-Q3 will be the tell on whether the ¥275 FY EPS consensus holds.
Cash flow & balance sheet (FY2025)
| Metric | FY2025 |
|---|---|
| Operating cash flow | ¥3.98B |
| Capex | ¥2.77B |
| Free cash flow | ¥1.21B |
| FCF margin | 5.8% |
| Cash & equivalents | ¥10.35B (yfinance Q1 ¥4.63B — reconciliation needed; likely reclass) |
| Total debt | ¥1.25B |
| Net debt | net cash position |
| ROE | 12.8% |
| ROA | 7.9% |
Balance sheet is clean — meaningful net cash, low leverage, fully funded capex programme.
Today’s growth comes from three places:
Capex pipeline:
Medium-term plan (2030 Vision Phase 2, Feb 13, 2026):
R&D. ~5-6% of revenue per Yuho, focused on (a) next-generation CZ chemistry for sub-0.1µm roughness, (b) AMALPHA bonding extensions, (c) photoresist-adjacent ancillary chemistry.
M&A. None disclosed; organic growth historically.
| Risk | Likelihood | Existing Mitigants | Mgmt De-risk Plan | Can It Be Closed? |
|---|---|---|---|---|
| AI/PCB demand cyclicality — revenue is now levered to hyperscaler capex cycles | Medium-High | Diversified end-use; six geographic bases; net cash buffers 1-2 quarter air pocket | Capacity expansion paced to qualified volume, not speculative | No — structural cyclicality |
| Customer concentration in ABF substrate cluster (Ibiden / Unimicron / Shinko) | Medium | 100% PC CPU substrate spec lock-in; multi-year qual moat | Active qualification work at Chinese substrate fabs (Suzhou) | Partially — closes if MEC is qualified into new entrants before share shift completes |
| Kitakyushu start-up cost drag on FY2026-FY2027 EPS | High (near-certain) | Margin guidance band 26-30% already factors depreciation | Phased ramp; revenue pre-booked | Yes — closes once Kitakyushu hits budgeted utilisation, late FY2027 / FY2028 |
| AMALPHA substitution risk (long tail) — hybrid-bonding or alternate direct-bonding | Low near-term, Medium 5-10yr | MEC owns AMALPHA — cannibalisation internalised | R&D allocation to AMALPHA extensions | Yes — if MEC’s own AMALPHA captures displacement |
| FX / JPY translation — non-Japan customers price in USD/TWD/CNY | Medium | Geographic production hedges some of this naturally | No active FX hedge programme disclosed | No — structural |
| Valuation re-rating risk (NEW vs 5/12) — analyst PT ¥8,900 vs spot ¥11,050 = -19.5% gap | Medium-High | Two-day -9.6% pullback from ¥12,230 high suggests market is starting to test the gap | None — management does not target stock price | No — closes only via earnings catch-up or further pullback |
Dilution risk. Effectively zero. Share count flat-to-declining. No convertibles, no warrant overhang, no ATM, no shelf disclosed. Net cash + FCF self-funds the Kitakyushu programme.
Key-person risk. Moderate. Family-influenced specialty chemicals company; CEO is long-tenured insider. Succession planning not disclosed in English. CZ know-how is tacit and lives in the R&D team, lowering true key-person risk relative to a typical founder-led small cap.
Major holder breakdown (per yfinance major holders):
| Holder | Type | Who They Are | Shares | % out | Filing |
|---|---|---|---|---|---|
| Vanguard Total Intl Stock Index | Passive index | Largest intl index fund; held via Japan small-cap weight | 211,970 | 1.08% | 2026-01-31 |
| Vanguard Developed Markets | Passive index | Developed-ex-US tracker | 139,594 | 0.71% | 2025-12-31 |
| Fidelity Japan Fund | Active Japan-focused | Active Japan equity mandate; thesis-driven small/mid stake | 128,600 | 0.66% | 2026-03-31 |
| Hood River International Opportunity | Active intl small-cap | Boutique intl small-cap; high-conviction stock-picker | 119,511 | 0.61% | 2026-01-31 |
| Vanguard International Explorer | Active intl small-cap | Vanguard’s outsourced active intl small-cap | 67,018 | 0.34% | 2026-01-31 |
| Dimensional Intl Small Cap | Factor / quant | DFA factor-weighted small-cap | 60,000 | 0.31% | 2026-01-31 |
| DFA Japanese Small Company | Factor / quant | DFA Japan small-cap | 57,800 | 0.30% | 2026-01-31 |
| Vanguard FTSE All-World ex-US | Passive index | Passive ex-US tracker | 54,400 | 0.28% | 2026-01-31 |
| Schwab Intl Small-Cap | Passive index | Schwab intl small-cap tracker | 30,188 | 0.15% | 2026-02-28 |
Top 9 holders together account for ~4.5% of shares — long-tail institutional ownership, no dominant active anchor. Hood River and Fidelity Japan are the only thesis-driven active holders of meaningful size. No 13D-equivalent activist filings. No identified PE/strategic.
yfinance returns no short-ratio data for 4971.T — Japanese short-interest runs through JSDA/JPX. Manual lookup required if material.
Japanese issuer — no SEC filings. Equivalent disclosures via TDnet:
The /filings 4971.T skill should pull these if it
supports JP issuers; otherwise the international filings monitor needs
an EDINET hook.
Searched ~/Dropbox/Wafflebun/KB/wiki/semianalysis/ for
4971 / MEC Company / CZ-series / copper surface treatment on 2026-05-15.
No direct SemiAnalysis coverage of MEC. No
contradiction or supporting SA piece to flag. Wafflebun’s
ai-server-pcb-primer.md flags MEC as an “indirect play”
with ~$2B market cap and ~15% supply-chain share — consistent with this
profile.
Profile refreshed 2026-05-15. Live data: yfinance. IR: MEC 2030
Vision Phase 2 (Feb 13, 2026). Cross-references:
~/Dropbox/Wafflebun/KB/wiki/ai-server-pcb-primer.md, prior
KB/wiki/4971/4971-profile.md (2026-05-12). SA mirror
cross-check: no direct coverage.
Verdict from 5/12 was PASS at ¥11,190; re-engage ¥7,000-9,000. Three days later:
The 5/12 verdict still holds. Nothing has changed the asymmetry — bear -61% / bull +18% over 12 months is still the framing. PASS at ¥11,050 / re-engage ¥7,000-9,000.
| Date | Close | Volume | Move |
|---|---|---|---|
| 2026-05-08 (Fri) | ¥10,360 | 431k | — |
| 2026-05-11 (Mon) | ¥10,630 | 355k | +2.6% |
| 2026-05-12 (Tue) | ¥11,190 | 478k | +5.3% (Q1 print) |
| 2026-05-13 (Wed) | ¥11,480 | 865k | +2.6% (4x avg vol, big institutional digestion) |
| 2026-05-14 (Thu) | ¥11,540 | 436k | new 52w intraday ¥12,230 |
| 2026-05-15 (Fri) | ¥11,050 | 147k | -4.2% on light volume |
20-day average volume is 337k. The 5/13 day (865k) is the institutional re-marking on the Q1 print; the two-day fade since looks like retail-shake / profit-taking on light volume, not distribution. The 52w high ¥12,230 stands as the level to clear for the next leg.
STF Research published “Finding the Last Cheap AI Stock in the Japanese Rally” on 2026-03-01 — an explicit MEC bull thesis at “around 20x P/E”. The current 40.5x TTM P/E means the STF thesis has played out cleanly: the stock has roughly doubled from the STF write date. STF’s three catalysts (PCB TAM expansion beyond substrate, substrate capex boom, AP-series misunderstanding clarified with IR) are now consensus, not edge. Full STF coverage at the end of this document.
The 5/12 framework stands with minor refinement:
NEW stop-loss / re-evaluate triggers:
Catalyst calendar (refreshed):
| Date | Event | Direction |
|---|---|---|
| Late May – mid Jun | Analyst PT revisions post Q1 print | Likely up — watch for upgrade cycle |
| 2026-06-29 | Ex-dividend | Mechanical |
| Aug 2026 (est) | H1 FY2026 print | Binary — H1 run-rate vs FY consensus ¥275 |
| Dec 2026 | Kitakyushu plant start | Margin drag begins (in plan) |
| Dec 2026 | Suzhou +30% capacity online | Volume capacity online |
The 5/12 risk table stands without modification. One risk has shifted in significance:
Valuation re-rate risk has moved from “High” to “Active.” The PT-vs-spot gap has widened in % terms as price has pushed higher; sell-side has not yet caught up. Two paths to close: analysts upgrade (constructive) or price drifts to PT zone (destructive). The next 4 weeks of broker notes will signal which.
Same as 5/12, with one addition:
PASS at ¥11,050. Re-engage at ¥7,000-9,000.
The 5/12 read held through Q1 print + 52w high + fade. Business quality remains best-in-class Japanese specialty chemicals; entry economics remain poor. Set price alerts at ¥9,000 and ¥7,000. Re-evaluate after analyst revision cycle (late May / mid June) and after H1 FY2026 print (Aug 2026). The next genuine decision point is Aug 2026.
The following sections from the 2026-05-12 entry are unchanged and form the canonical reference:
See ~/Dropbox/Wafflebun/KB/wiki/4971/4971-deep-dive.md
(5/12 version, now superseded by this refresh) for the full text. The
supersession is intentional: this delta version replaces the prior file
in vault on sync.
KB/wiki/4971/4971-deep-dive.md
(2026-05-12); ai-server-pcb-primer.md;
packaging-glass-substrate-primer.md;
4971-vs-4062-vs-5706-showdown.md.Source: STF Research, “Finding the Last Cheap AI
Stock in the Japanese Rally” (2026-03-01, paid Substack post on
stfbutnou.substack.com). Pulled via opencli browser session
2026-05-15.
Date context: STF wrote when MEC traded at “around 20x P/E.” MEC’s TTM P/E today is 40.5x; the stock has roughly doubled since the STF write date. STF’s thesis has played out cleanly in 75 days. STF has not published a post-rally follow-up on MEC as of 2026-05-15.
STF’s MEC framework — the three catalysts they identified:
PCB Expansion Catalyst (TAM expansion). STF flagged that consensus assumed CZ-series was exclusively used on packaging substrates, but their channel work showed CZ is required directly on HDI PCBs in advanced AI server architectures. “Current company guidance does not fully price in this massive TAM expansion onto the broader PCB market, setting the stage for significant upward earnings surprises.” This is the central STF edge call.
Substrate CAPEX Boom. Multi-year locked-in demand from substrate-fab capex (Ibiden, Unimicron, Shinko expansions) translates to multi-year chemicals demand. STF framed this as “potential supply shortages for the critical chemicals required to run these new facilities.”
AP Series Misunderstanding. STF reached out to MEC IR directly and confirmed that the AP-series forecast cut (which spooked some investors) is timeline maturity, not product failure: “The broader market development simply is not fast enough yet to necessitate the AP product on current substrates… The core CZ-series business remains robust and completely unaffected by this early-stage product delay.”
STF’s framing on the moat: “Substrate companies simply have no choice but to purchase MEC’s high-quality products. The risk of yield loss from utilizing a cheaper, unverified alternative far outweighs the cost of MEC’s premium chemicals. This dynamic creates a captive customer base, allowing MEC to maintain absolute pricing power during a period of explosive structural volume growth.” — Consistent with the deep-dive moat analysis (qualification cost, spec lock-in, asymmetric pricing power).
STF’s HVLP4 angle (new vs prior vault entries). STF positions MEC explicitly as “an unrecognized HVLP4 player” — i.e., the chemistry side of the HVLP4 (very-low-profile copper foil) transition. The 5/12 vault entries focused on roughness-control and dielectric-loss; the HVLP4 framing is adjacent but valuable because it ties MEC to the same supply-chain narrative that drives the Mitsui Mining & Smelting / Furukawa Electric / Fukuda Metal HVLP4 thesis tracked elsewhere in the vault. Add this framing to the AI PCB primer cross-reference next pass.
STF’s quoted MEC IR confirmation is a meaningful data point — it shows STF has at least preliminary IR access. This is consistent with their pattern of Japanese supply-chain hidden-gem coverage (Uyemura 4966, Kitagawa Seiki, Taiyo Holdings, Furuya Metal).
Cross-reference with our deep-dive:
| STF claim | Our 5/12 view | Status |
|---|---|---|
| CZ used on PCBs not just substrates | Same — described as HDI mobile PCB + AI server PCB use case | Consistent |
| AP-series forecast cut = timing not failure | Flagged in /mgmt-dd; not detailed in 5/12 deep-dive | STF adds IR confirmation |
| MEC is monopolistic HVLP4 chemistry play | Implied via CZ ~100% PC CPU substrate share; HVLP4 framing not explicit | STF adds new framing — incorporate next pass |
| ~20x P/E undervalued (at Mar-1-2026 write) | Stock has since doubled to 40.5x TTM | STF was right; thesis now consensus |
No STF coverage found across these posts when scanned for MEC mentions (length verified > 1k chars, no paywall block): - “AI Supply Chain: Shortage Intensifying Toward 2027” (Apr 7, 2026 — paid) - “Updates on Our Japan Hidden Gems Picks and Taiyo Holdings” - “Kitagawa Seiki: Hidden Champion ‘Pressing’ the AI Era Together” - “Uyemura: Another Invisible Beneficiary Behind Every Substrate”
Substack Chat: STF Research does not maintain a separate subscriber chat (chat URL redirects to a recent post). No chat-level commentary on MEC available.
Net read of STF view: Their thesis was right and is now consensus. There is no STF-specific edge or contradiction with the current vault view, but their HVLP4 framing and direct IR confirmation on AP-series timing are two factual additions worth carrying into the next deep-dive refresh.
Filed 2026-05-12 (Tuesday, post-market Tokyo). Three things to flag from a governance lens:
Earnings forecast revision filed alongside Q1 print. Japanese disclosure convention is to revise full-year guidance whenever Q1 results diverge materially from the path embedded in the prior forecast. MEC chose to revise. Direction implied is upward (consistent with the dividend revision filed in parallel).
Dividend forecast revision filed alongside Q1 print. This is the higher-signal disclosure: MEC’s capital return policy is 35%+ payout + 4%+ DoE + opportunistic buybacks (per 2030 Vision Phase 2). The dividend revision means management is signalling confidence that the full-year denominator (EPS × payout %) supports a higher absolute distribution. Management has historically been conservative on dividend guides — they rarely revise unless they have line-of-sight on a beat.
EPS ¥25.44 on 18.73M weighted shares. No granular segment disclosure surfaced in the public English filing yet. Full Tanshin PDF / Yuho would close that gap. Governance flag (minor): English-language disclosure pace at MEC remains a beat behind the Japanese-language Tanshin. Not unusual for TSE Prime small-cap chemicals, but a friction point for non-Japanese institutional analysts.
STF Research, a paid Substack equity-research publication, disclosed in their 2026-03-01 MEC post that they had received direct confirmation from MEC IR on the AP-series forecast cut — specifically that the AP forecast was reduced because “the broader market development simply is not fast enough yet to necessitate the AP product on current substrates… The core CZ-series business remains robust and completely unaffected by this early-stage product delay.”
Governance read: MEC IR is engaging directly with sell-side research (paid Substack publishers are an emerging proxy for traditional sell-side research). This is modestly positive — MEC has historically had a thin English-language IR posture for a TSE Prime listed name, and the willingness to clarify a forecast cut directly to an external researcher suggests improving IR responsiveness. Compare with the 5/12 mgmt-dd flag that English IR materials lagged Japanese.
Governance read: Thin coverage at the institutional level is a structural feature of Japanese small-cap chemicals, not a red flag. But: the drop from 3 to 2 happening as the stock punches 52w highs is worth noting. If a covering analyst exited rather than upgraded, that is a small negative signal on near-term consensus path.
The following sections from the 5/12 entry remain canonical and require no update:
| Name | Role | Shares | % out | Est. value |
|---|---|---|---|---|
| Kazuo Maeda | CEO & President | ~727K | 3.98% | ~$49M |
| Sadamitsu Sumitomo | Director, EOO Global Ops | ~20K | 0.11% | ~$1.4M |
| Mitsutoshi Takao | Outside Director (AC Chair) | ~3K | 0.016% | ~$202K |
| Kaoru Hashimoto | Outside Director (AC) | ~600 | 0.0033% | ~$40K |
| Eiji Miyashita | Outside Director (AC) | ~500 | 0.0027% | ~$34K |
Aggregate insider stake 18.45% (per yfinance major holders). No insider buys or sells in last 6 months.
The governance picture remains clearly positive for a TSE Prime mid-cap Japanese specialty chemicals name:
The few items to track for the next pass:
Governance: PASS. Long-tenured operator-CEO with meaningful skin in the game, clean board structure, committed and executed capital return policy, improving IR responsiveness. No red flags. Governance is not the question on this stock — valuation is.
KB/wiki/4971/4971-mgmt-dd.md
(2026-05-12, superseded by this refresh).Live snapshot (yfinance, 2026-05-12 close):
| 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku | |
|---|---|---|---|
| Price | ¥11,190 | ¥16,550 | ¥50,850 |
| 1-year return | +340% | +570% | +1,181% |
| YTD return | +116% | +132% | +175% |
| 52w high / low | 11,780 / 2,385 | 18,365 / 2,426 | 53,200 / 4,030 |
| Market cap | ¥204B (~$1.3B) | ¥4.6T (~$30B) | ¥2.9T (~$19B) |
| Enterprise value | ¥200B | ¥4.3T | ¥3.0T |
SA mirror cross-check: Multiple SA pieces touch the AI-substrate stack (GB200 component teardown 2024, Blackwell rework 2024, Vera Rubin GTC 2025, advanced packaging 2022). Each deep-dive cross-checked SA — no contradictions surfaced. SA classifies 5706 as “bottleneck tier” in the AI-server PCB primer mirror.
| Metric | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| Company | MEC Company Ltd. | Ibiden Co., Ltd. | Mitsui Kinzoku |
| Sector / Industry | Specialty Chemicals — PCB/substrate adhesion | Electronic Components — IC substrate | Diversified Metals — Cu foil + smelting |
| Stack position | Chemistry into PCB/substrate (CZ copper microetchant) | IC substrate fabricator (ABF FCBGA) | Cu foil into CCL (MicroThin + VSP) |
| Market cap | ¥204B | ¥4.6T | ¥2.9T |
| 52w performance | +369% | +582% | +1,162% |
| YTD performance | +116% | +132% | +175% |
| Div yield | 0.9% | 0.26% | 0.47% |
| Beta | 1.06 | 1.56 | 1.37 |
| 50d MA / Price | ¥7,832 / ¥11,190 | ¥9,901 / ¥16,550 | ¥35,550 / ¥50,850 |
| 200d MA / Price | ¥5,333 / ¥11,190 (+110%) | ¥6,841 / ¥16,550 (+142%) | ¥20,837 / ¥50,850 (+144%) |
| Analyst mean PT | ¥8,900 (-20% vs spot) | ¥10,441 (-37% vs spot) | ¥41,567 (-18% vs spot) |
| Analyst high PT | ¥10,000 (-11%) | ¥18,400 (+11%) | ¥56,700 (+12%) |
| # analysts | 2 (thin) | 17 | 9 |
All three: spot above analyst mean PT. Sell-side hasn’t caught up. The question is whose spot is the cleanest mispricing — and for which one will revisions catch up vs roll over.
| Dimension | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| Revenue model | Specialty chemistry — sold per litre/kg into PCB and substrate fabs | Engineered substrates — sold per panel to packagers (Intel, AMD, Nvidia) | Cu foil + smelting — sold per roll to CCL makers + per tonne to industrial users |
| Revenue segments | Chemicals (CZ + AP + auxiliary) ~95%+; equipment 5% | Electronics ~75% (substrates), Ceramics ~20%, Other ~5% | Engineered Materials ~35% (Cu foil ~14% of group), Metals ~41% (smelting), Mobility ~20% (exiting), Other |
| Customer concentration | Diversified — sold to substrate fabs (Ibiden, Unimicron, Kinsus, AT&S, etc.); single largest <15% | Concentrated — Intel + Nvidia + AMD = >60% of substrate revenue; top-1 Intel ~30% | Estimated top-1 (Ibiden) 12-18%; top-3 30-40%; broader CCL base than 4062 |
| Competitive moat | Process / spec moat — 20yr ~100% PC CPU substrate share on CZ chemistry; CZ-8101 qualified into CoWoS chiplet packaging | Process / scale moat — 35yr ABF substrate franchise; Oono phase 2 capex contrarian bet locks high-end capacity | Process / spec moat — >90% global share in premium-grade circuit Cu foil (MicroThin carrier foil + VSP) |
| Moat strength | Strong within high-end CZ (alternatives can’t hit the roughness/adhesion spec) | Strong at flagship-tier ABF substrate; weakening if glass-core transitions by 2030 | Strong at premium grades; Korean/Chinese H-VLP3 catching up is the medium-term threat |
| TAM & penetration | Small TAM (~$2-3B specialty PCB chemistry) but high penetration | Mid TAM (~$15-20B ABF substrate + ceramic packages) with #1 share | Medium TAM (~$8-10B premium Cu foil) with >90% share at the top tier |
| Secular tailwinds | AI-PCB layer-count expansion; more-treatment-per-layer; CZ-8101 into CoWoS | AI accelerator substrate area scaling (3,025→8,100mm²); FY27 EPS growth from Oono | AI-server ABF substrate growth = Cu foil per substrate area; MicroThin USD +12% (Apr 2026); FY27 ROIC 27→49% |
Business model takeaway: - Most durable moat: 4971 — the smallest TAM but 100% share at the most spec-sensitive node. CZ is the “Intel Inside” of substrate chemistry. - Largest runway for growth: 5706 — single-product (Cu foil) growth into a structurally undersupplied market, layered onto a wrapper that the market still prices like a smelter. - Most market-cap-leveraged to AI: 4062 — already the largest of the three (¥4.6T) and the most directly tied to Nvidia substrate ramps. - Red flag scan: none of the three is structurally broken. The Mobility exit at 5706 is mgmt-engineered (disposing low-margin auto-parts) not crisis-driven.
| Metric | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| Revenue (TTM) | ¥12.0B | ¥415B | ¥729B |
| Revenue growth (YoY) | +87.7% | +18.6% | +0.1% (group flat; Cu foil +50%+) |
| Gross margin | 61.6% | 31.6% | 22.9% |
| Operating margin | 27.4% (FY25E) / 15.4% (TTM) | 14.1% | 17.9% |
| Net margin | 14.5% | 15.3% | 8.5% |
| ROE | 12.8% | 12.2% | 18.4% |
| ROA | 7.9% | 3.6% | 8.7% |
| Metric | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| Operating cash flow | n/a (yfinance gap) | ¥106B | n/a (yfinance gap) |
| Free cash flow | n/a (yfinance gap) | −¥47.5B (capex peak) | n/a (yfinance gap) |
| Total cash | ¥4.6B | ¥296B | ¥43B |
| Total debt | ¥1.25B | ¥193B | ¥136B |
| Net cash / (debt) | +¥3.4B (net cash) | +¥103B (net cash) | −¥93B (net debt; ND/EBITDA ~1.0x per deep-dive) |
| Shares out | 18.3M | 279M | 57.2M |
Financial health ranking: 1. 4971 MEC — net cash, 62% GM, no FX exposure ex-USD pass-through. Cleanest balance sheet. 2. 4062 Ibiden — net cash but capex peak driving negative FCF; through-cycle financial health A. 3. 5706 Mitsui Kinzoku — modest leverage (ND/EBITDA 1.0x) but ROIC 11% and rising. Conglomerate cash conversion clouded by zinc/lead working capital.
| Metric | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| Revenue growth TTM | +88% | +19% | +0.1% (group) / +50%+ (Cu foil) |
| Earnings growth TTM | -17% (Y/Y comparison includes 2025 SBC-loaded) / FY25E EPS +90% per deep-dive | +247% | +99% |
| 3Y rev CAGR forward (per deep-dives) | ~20-25% (CZ-8101 ramp) | ~25-30% (Oono phase 2) | ~10-15% (Cu foil-led) |
| FY27 plan vs trajectory | Running ahead — Phase 2 OPM 28% vs ≥20% target; ROE 15% vs ≥10% | Running ahead — multi-year targets exceeded | Running far ahead — Feb 2026 raise already hits FY27 OI target a year early |
Growth drivers — by stock:
4971 MEC (0-24mo): 1. Kitakyushu plant Dec-2026 start adds ~30% capacity at the high-end 2. Suzhou +30% expansion by Dec-2026 3. CZ-8101 qualified into CoWoS chiplet packaging — secular AI exposure
4062 Ibiden (0-24mo): 1. Oono Phase 2 commissioning unlocks FY3/26 +34% rev consensus 2. Vera Rubin substrate supplier disclosure (H2 2026) 3. Q2 FY3/26 earnings (Jul-Aug 2026) — most consequential print
5706 Mitsui Kinzoku (0-24mo): 1. FY2025 full-year print TOMORROW May 13 + FY26 initial guide (binary catalyst) 2. 12% USD MicroThin price hike eff April 20 2026 — pricing power test 3. CEO transition April 1 2026 — Ikenobu Seiji (Cu-foil insider) takes over
Growth ranking: 1. 5706 — highest absolute growth in the Cu foil segment (foil ROIC 27→49% by FY30 per mgmt plan); but consolidated number gets diluted by smelting 2. 4062 — fastest forward EPS growth (consensus revisions still catching up post May print) 3. 4971 — smallest base, highest GM, but limited capacity to run faster than capex allows
| Multiple | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| P/E (TTM) | 41.1x | 77.2x | 62.4x |
| P/E (NTM) | 57.7x | 53.6x | 84.5x |
| EV/EBITDA (TTM) | 69.6x | 34.4x | n/a |
| EV/Revenue (TTM) | 16.7x | 10.3x | 4.2x |
| P/B | 14.7x | 8.5x | 8.0x |
| Stock | TTM P/E | 5Y avg P/E | Premium | Justified? |
|---|---|---|---|---|
| 4971 | 41x | ~22x | +86% | Partially — 28% OPM trajectory and FY27 sandbagging, but stretched |
| 4062 | 77x | ~25-30x (cyclical) | +150%+ | No — even bull-case FY3/27 EPS at 50x is below spot |
| 5706 | 62x | ~12-15x (smelter) | +300%+ | Yes — if you SOP the Cu foil sub at specialty-chem multiples (18-25x EV/EBIT) |
| Stock | DCF / SOP fair value range | Spot | Implied upside |
|---|---|---|---|
| 4971 | ¥6,500-9,000 | ¥11,190 | -20% to -42% to fair value |
| 4062 | ¥11,000-15,000 (DCF); ¥15,103 prob-weighted target | ¥16,550 | -9% to fair value (symmetric, modestly bear) |
| 5706 | ¥34,000 (SOP base, FY30 discounted to today); ¥63,000 (12M target) | ¥50,850 | +24% to 12M base case (with binary Q4 print as gating event) |
| Metric | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| ROIC | ~25-30% (per deep-dive) | ~10-12% (segment ~25%) | 27% (Cu foil); 11% (consolidated) |
| ROE | 12.8% | 12.2% | 18.4% |
| Insider ownership | 18.5% (incl. CEO 4%) | <2% (typical JP) | 4.1% |
| Recent insider activity | Neutral; SBC ~0.18% | Neutral | Neutral |
| Buyback yield TTM | Modest (¥1.29B FY25 + cancel 500k Aug 2025) | Inadequate (¥641M at FY3/25 trough when ¥50-100B was right) | Steady; dividend policy preferred over buyback |
| Dividend growth | 35%+ payout + 4%+ DoE (upgraded mid-MTP) | Standard JP payout | 35%+ payout + 3.5%+ DoE; FY25 DPS ¥240 (raised) |
| Capital allocation grade | A (deep-dive) | B+ (mgmt-dd) | A- (mgmt-dd) |
| Risk Dimension | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| Cyclicality | Moderate | High (substrate cycle) | High (zinc/lead + Cu foil cycle) |
| Customer concentration | Low (diversified) | High (Intel + Nvidia + AMD >60%) | Moderate (top-3 30-40%) |
| Regulatory | Low | Low | Moderate (smelter environmental, Atalaya feasibility) |
| Leverage | Negligible | Low (net cash) | Moderate (ND/EBITDA 1.0x) |
| Key-person | High (CEO 24yr / no named #2) | Low | Low (succession formalized) |
| Competitive disruption | Medium (AP-series no-roughening for Gen-N+ is next platform) | Medium-High (glass-core 2030 transition) | Medium (Korean/Chinese H-VLP3 catch-up) |
| Macro sensitivity | Medium (USD pass-through; PCB cycle) | High (substrate cycle, China FX) | High (LME zinc/lead, yen) |
| Valuation | High (41x TTM vs 22x norm; sell-side -20%) | High (77x TTM; sell-side -37%) | High (62x TTM; sell-side -18%) |
| Technical Dimension | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|
| Trend (50d vs 200d MA) | Above both | Above both | Above both |
| RSI (14d, per deep-dives) | ~73 (overbought) | ~70 (overbought) | ~75+ (overbought) |
| % from 52w high | -5% | -10% | -4% |
| % above 200dMA | +110% | +142% | +144% |
| Recent volume trend | Accumulation Q1 26 → distribution warning at 52w high | Accumulation post Q1 print | Heavy accumulation Feb-Apr 2026 |
| Near-term setup | Unfavorable | Unfavorable | Binary (tomorrow’s print) |
Technical verdict: All three are stretched. None should be chased into the print. 5706 is the only one with a near-term catalyst that can resolve the technical extension either way. 4971 and 4062 need cooling-off (a 15-25% pullback) before a clean entry exists.
| Dimension | Weight | 4971 MEC | 4062 Ibiden | 5706 Mitsui Kinzoku |
|---|---|---|---|---|
| Business Quality | 20% | 5/5 | 4/5 | 5/5 |
| Financial Health | 15% | 5/5 | 4/5 | 3.5/5 |
| Growth | 20% | 3.5/5 | 4.5/5 | 4.5/5 |
| Valuation | 20% | 2/5 | 2.5/5 | 3.5/5 |
| Quality & Capital Allocation | 10% | 5/5 | 3.5/5 | 4.5/5 |
| Risk (inverted, lower=better=higher score) | 10% | 3.5/5 | 3/5 | 2.5/5 |
| Technical Timing | 5% | 2/5 | 2/5 | 2.5/5 |
| Weighted score | 100% | 3.65 | 3.50 | 3.80 |
| Rank | Ticker | Score | Verdict | One-line rationale |
|---|---|---|---|---|
| 1 | 5706 Mitsui Kinzoku | 3.80 | WATCH → BUY pending FY26 guide ≥¥130B OI | Only stock where SOP fair value > spot; binary catalyst tomorrow can resolve the trade |
| 2 | 4971 MEC | 3.65 | WATCH at ¥7-9k re-entry | Highest quality + cleanest balance sheet; spot is 20-42% above DCF |
| 3 | 4062 Ibiden | 3.50 | WATCH at ¥14-14.5k or post sell-side PT revision | Quality franchise but symmetric risk/reward; consensus catch-up trade either re-rates or unwinds |
5706 Mitsui Kinzoku — but after the May 13 FY26 initial guide, not before. The other two are quality businesses at the wrong price; 5706 is a quality business with a visible mispricing path (sum-of-parts-into-specialty-chem multiple) that no amount of waiting will necessarily fix on its own. The print is the gate. Guide ≥¥130B OI → tranche 1 (50% of intended position) at ¥45-48k. Guide <¥120B OI → walk away, revisit after a ¥35-40k sector drawdown.
Skip the diversification frame. These three are positively correlated (same AI-substrate macro factor). Owning all three is one trade with extra slippage. Pick one and size it; or wait for one to crack and pick the best of the survivors. The cleanest combination would be 5706 (post-print, mispricing thesis) + a 4971 starter at ¥7-9k (quality compounder ballast) — that combination separates the thesis trade from the quality compounder. Skip 4062 unless sell-side targets revise into the JPY 18-22k range, at which point the consensus-catch-up trade is over and the franchise stands on its own.
Pre-delivery checklist: - Redundancy sweep: references deep-dive material rather than duplicating; tables consolidate, do not repeat - Word justification: each table earns space — composite scorecard is the load-bearing synthesis - Register D pass: declarative, no hedge phrases, position-taking; “Pick one and size it” is the verdict